enGene next stop for Ron Cooper

24 July 2024

Genetic medicines company enGene Holdings (Nasdaq: ENGN) has named Ron Cooper (pictured, above) its new chief executive.

This transition follows a previously announced succession plan for Jason Hanson, who will remain a strategic advisor to the company, which is conducting a pivotal study with its non-viral, intravesical lead product candidate, EG-70, in BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).

Mr Cooper most recently served as president and chief executive of Albireo Pharma, a fully integrated global commercial biopharmaceutical company that Ipsen (Euronext: IPN) acquired in 2023.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology